With just a few short days left in the fall calendar, I better get busy wrapping up my travel log of an October trip to ...
Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
The Phase 1b study is designed to evaluate the safety and tolerability of orally administered balomenib over a 28-day treatment period, followed by a post-treatment observation phase of up to ...
Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and ...
After Holy City was razed in 135 CE, an edict seemed designed to prevent a Jewish return. The discovery of an ancient ...
Stocktwits on MSN
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal?
CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. ・The study ...
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 ...
Detailed price information for Avant Technologies Inc (AVAI) from The Globe and Mail including charting and trades.
Investing.com -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock rose 5% after reporting positive results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist being developed for ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...
Average Upside Potential as of December 10: 104.08% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback